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ABSTRACT 
Objective: The present study aimed to prepare LL-37 in a cream formulation (O/W emulsion) and evaluate its stability by determining the physical 
changes in the cream and concentration of LL-37 using validated high-performance liquid chromatography. 
Methods: The method was conducted at room temperature using a C18 column (5 µm × 250 mm × 4.6 mm) as a stationary phase, a mixture of 0.1% 
trifluoroacetic acid (TFA)/water (A) and 0.1% TFA/acetonitrile (B) (85:15) as the mobile phase, a flow rate of 1.0 mL/min, an d photodiode array set 
at 228 nm as the detector. The method was validated in compliance with the Association of Official Analytical Chemists and International Conference 
on Harmonization guidelines. It demonstrated excellent linearity, accuracy, precision, specificity, the limit of detection, and limit of quantitation. 
Results: The chromatographic analysis indicated minimal degradation of LL-37 during the 12-week, with a predicted expiry time of 99 and 75 mo 
stored at 4 °C and 28 °C, respectively.  
Conclusion: LL-37 cream establishes good physical characteristics and stabilizes the active ingredient, especially at 4 °C and 28 °C storage. 
Therefore, the emulsion delivery system of LL-37 cream is harmless and stable as a novel alternative vehicle of LL-37. 
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INTRODUCTION 
Diabetic foot ulcer (DFU) is one of the major complications resulting 
from diabetes. The prevalence of the disease worldwide is estimated 
at 6.3% [1]. The treatment of DFU is still challenging and often 
achieves unsuccessful outcomes. Infection control, pressure relief, 
wound debridement, and revascularization are the main principles 
of DFU management [2]. Numerous studies have been conducted to 
evaluate several therapeutic agents’ promising effects, including an 
antimicrobial peptide released upon wounding, LL-37, in treating 
DFU. LL-37 originates from the 18 kDa human cathelicidin 
antimicrobial protein (hCAP18) [3].  
The upregulation of hCAP18/lL-37 expression occurs within several 
hours after acute wounding, and the protein is released toward the 
wound edges through basal epidermal keratinocytes [4]. However, 
although hCAP18 mRNA is highly expressed in chronic ulcer 
epithelium, the translated protein is absent, suggesting the defects in 
translation or rapid degradation of mRNA [3, 5]. Moreover, LL-37 
antibodies were demonstrated to prevent re-epithelialization in an 
ex vivo human wound healing model [6]. Thus, hCAP18/lL-37 
contributes to the biological process of wound healing. Experimental 
murine models showed that LL-37 could enhance the wound healing 
process, although the results showed inconsistencies [7, 8]. The 
efficacy of topical administration of LL-37 in stimulating wound 
healing of venous leg ulcers was demonstrated previously [9].  
Previous studies that used LL-37 in solution form as the vehicle 
showed its excellent effectivity. However, pharmaceuticals in solution 
preparation do not stay on the wound bed and require frequent 
administration [9, 10]. Cream (O/W emulsion) may stay for an 
extended period on the wound bed and is more practical for home use. 
Studies regarding the preparation of LL-37 in the cream have not been 
explored yet, including its stability. Accordingly, the present study 
aimed to prepare and investigate the stability of cream containing LL-
37, which could be a novel alternative vehicle of LL-37. 
MATERIALS AND METHODS 
Materials 
A pharmaceutical-grade chemical was used for cream preparation 
(Brataco, Indonesia). The active material, LL-37 (purity>95%), was 
purchased from Isca Biochemicals (Exeter, UK). The chemicals used for 
analysis, such as methanol, acetonitrile, and trifluoroacetic acid (TFA), 
were of chromatographic grade (Merck, Germany), whereas distilled 
water was obtained from PT. Ikapharmindo Putramas, Indonesia. For the 
cream stability test experiment, the stability testing chamber (Nuve, TK 
120, Turkey) was used. The liquid chromatographic analysis was 
conducted using an LC 20AD HPLC system and a pump (Shimadzu, 
Japan), provided with SPD-M20A photodiode array (Shimadzu, Japan), a 
manual injector (Rheodyne, USA), and XBridge, BEH 300, C18 column 
(5 µm × 250 mm × 4.6 mm; Waters, USA). Shimadzu LC Solution 1.24 SP2 
was operated to process and evaluate the data.  
Methods 
Cream preparation  
Table 1 displays the composition of the cream base (O/W emulsions). A 
heated solution consisting of glycerin and distilled water was added to 
the heated mixture of stearic acid, cetyl alcohol, triethanolamine, and 
liquid paraffin. The resulting mixture was homogenized using an 
automatic stirrer for 15 min at 3000 rpm. The acidity of the emulsion 
was measured and adjusted to pH 6.28 by the addition of citric acid. 
Finally, a solution of LL-37 in distilled water was added to the emulsion 
and homogenized. The final emulsion contained 0.5 mg/ml LL-37. 
 
Table 1: Compositions of cream base 
Ingredients Formulation (%) 
Stearic acid 7 
Cetyl alcohol 2 
Triethanolamine 0.5 
Liquid paraffin 20 
Glycerin 10 
Distilled water 59.5 
 
High-performance liquid chromatography (HPLC)  
Preparation of standard solution 
LL-37 10 mg was dissolved in 10 ml mobile phase, and the resultant 
solution was diluted by a similar solvent to obtain a concentration of 
0.5 mg/ml. 
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Preparation of sample solutions 
One gram of LL-37 emulsion was dissolved in 10 ml mobile phase, 
sonicated for 10 min, and then filtered using a 0.45 µm membrane 
filter. 
Chromatographic conditions 
The chromatographic conditions were accomplished as per a former 
report [11] to optimize the ratio of mobile phase compositions. A 
mixture of 0.1% TFA solution in water (A) and 0.1% TFA solution in 
acetonitrile (B) was applied as a mobile phase with a flow rate of 1 
ml/min. The SPD-M20A photodiode array was operated at 228 nm 
for the identification and quantification of the analyte. 
Chromatographic analysis was performed at ambient temperature 
and 20 µl volume injection and running time of 10 min. 
Method validation 
Method validation was conducted following the Association of 
Official Analytical Chemists (AOAC) and International Conference on 
Harmonization (ICH) guidelines for specificity, linearity, the limit of 
detection (LOD), the limit of quantitation (LOQ), accuracy, and 
precision [12, 13]. 
Specificity 
Specificity was tested by analyzing the solvent, mobile phase, cream 
base, LL-37 emulsion (0.5 mg/ml), and standard solution of LL-37 
(0.5 mg/ml). Related peaks were examined for retention times and 
peak interference. 
Linearity, LOD, and LOQ 
Five separate concentrations were prepared (0.1, 0.25, 0.5, 0.75, and 
1 mg/ml) to evaluate the linearity of the method. The analysis of a 
single injection from a respective concentration was performed 
correspondingly. A calibration curve was then constructed from the 
data, and the correlation coefficient was determined. The LOD and 
LOQ of LL-37 obtained using this method were derived from the 
calibration curve using statistical analysis [12, 13]  
Accuracy and precision 
The method’s accuracy and precision were determined at three 
different spiked concentration levels (80%, 100%, and 120%) 
adjacent to the test concentration (LL-37 0.5 mg /ml) by nine 
determinations (three replicates were prepared using the respective 
concentrations). The percentage recovery and relative standard 
deviation (RSD) were estimated for every replicate sample to 
evaluate accuracy and precision. 
Stability test 
The stability test was conducted using an accelerated stability test 
method to explore the effect of storage regarding the emulsion’s 
chemical and physical substances [14, 15]. The tests were conducted 
on samples stored in the stability testing chamber at 4 °C±2 °C, 28 
°C±2 °C, and 40 °C±2 °C at 75% room humidity. Alterations of 
liquefaction, color, odor and phase separation were recorded every 
two weeks, with a total of 12 w. The emulsion pH was determined 
using a digital pH meter every two weeks of storage. The 
concentration of LL-37 in the cream emulsion was analyzed using 
HPLC at 0, 4, and 12 w. 
RESULTS AND DISCUSSION 
Optimization and validation of HPLC method 
Method optimization 
The wavelength at 228 nm, the flow rate at 1.0 ml/min, and a 
mixture of mobile phases A and B (85:15) were achieved for the 
analysis. The results of the system suitability test of the method 
showed that the % RSD values for retention time and area under the 
curve were 0.51% and 0.14%, respectively, with mean tailing factors 
of 1.57±0.14. The results for % RSD and tailing factor are within the 
acceptance criteria (fig. 1). 
  
 
Fig. 1: Chromatogram of LL-37 standard solution 
  
 
Fig. 2: Calibration curve of LL-37 
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The LL-37 standard solution chromatogram, LL-37 cream, solvent, 
matrix, and mobile phase showed no interference on or adjacent to the 
LL-37 peak by solvent, matrix, or mobile phase (fig. 3), indicating the 
specificity of the method. To the best of our knowledge, this is the first 
validation study for LL-37 formulated in cream. The previous study 
has reported the analysis of LL-37 in polymeric gels using HPLC 
method, which demonstrated little to no interference. A plausible 
explanation could be due to the hydrophilic materials of polymers 
which causes an insignificant reaction with the analytical column. 
Given the fact that cream (O/W) is similarly hydrophilic, this could 
attribute to the negligible interaction of the present study [16]. The 
method’s accuracy, which ranged from 99.28% to 101.50%, was 
demonstrated using a % recovery study. The precision was 
determined from % RSD at concentrations of 0.4, 0.5, and 0.6 mg/ml 
LL-37, with values reaching 0.11%, 0.23%, and 0.65% respectively. 
These results met the criteria for accuracy and precision [12, 13]. 
 
 
Fig. 3: Chromatogram of (A) LL-37 standard solution; (B) LL-37 cream; (C) matrix; (D) solvent; and (E) mobile phase 
 
Stability of prepared cream 
Table 2 demonstrates the alterations of liquefaction, color, and odor. 
The results showed white emulsions after preparation. No colour 
changes was detected at different storing temperatures (4 °C, 28 °C, 
and 40 °C) up to 12 w of observation. The increment in temperature 
and time influenced the separation of emulsion, which reduced 
viscosity and resulted in liquefaction. In this study, the liquefaction 
of emulsions was absent at 4 °C and 28±2 °C storage conditions 
during 12 w of observation. Liquefaction was observed for the 
emulsion at 40± °C storage starting at week 4, indicating the 
emulsion’s instability as reported in another study [17]. The absence 
of liquefaction at 4 °C and 28 °C storage conditions demonstrated 
compelling support regarding this emulsion’s stability under cold 
and room temperatures. A similar pattern of results was obtained 
with a study using a non-steroidal anti-inflammatory drug cream 
which demonstrated good physical characteristic within room 
temperature for 3 mo [18]. 
 
Table 2: Physical characteristics of LL-37 cream stored at 4±2 °C, 28±2 °C, and 40±2 °C 
  Baseline 2 w 4 w 6 w 8 w 10 w 12 w 
Liquefaction 4 °C - - - - - - - 
 28 °C - - - - - - - 
 40 °C - - + + + + + 
Color 4 °C - - - - - - - 
 28 °C - - - - - - - 
 40 °C - - - - - - - 
Odor 4 °C - - - - - - - 
 28 °C - - - - - - - 
 40 °C - - - - - - - 
−= Negative/no change; += Positive  
 
The alteration of pH implies the consequence of chemical reactions, 
providing insights into the outcome’s quality. The ideal pH of human 
skin varies from 4.5 to 6.0. LL-37 cream preparation should have a 
pH that is close or within this range to exert its optimal function and 
possibly gain regulatory approval. The emulsions prepared in this 
study yielded a pH of 6.28, close to the pH of natural skin. 
Furthermore, storing the emulsion samples at different 
temperatures (4 °C, 28 °C, and 40 °C) may continually reduce the pH 
during the 12 w of observation. Destabilization of the emulsion 
through hydrolysis occurred during storage at elevated 
temperatures [13]. These findings are in line with a previous study 
using an anti-wrinkle cream which demonstrated that higher 
temperatures resulted in increased viscosity [19]. As evidenced in 
this study, storing the emulsions at 4 °C, 28 °C, and 40 °C resulted in 
an acceptably stable pH at nearly 6.0, which is tolerable and gentle to 
the skin.  
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The concentration of LL-37 in cream preparation during the 12 w of 
storage at various temperatures showed minimal degradation (table 
3, fig. 4). Linear regression analysis between the ln concentrations of 
LL-37 at 4 °C, 28 °C, and 40 °C against time indicated that the 
degradation periods needed by the compound to reach 90% of the 
initial concentration were 99, 75, and 16 mo, respectively. 
 
Table 3: LL-37 concentration at various temperatures during 12 w of observation 
Storage condition Mean LL-37 concentration (mg/ml) 
Baseline 4 w  12 w 
4 °C 0.492 0.491 0.491 
28 °C 0.493 0.492 0.491 
40 °C 0.512 0.508 0.500 
 
 
Fig. 4: Linear regression graph of LL-37 stability 
 
CONCLUSION 
The preparation and stability study of LL-37 cream has been 
conducted successfully. Quantitation of LL-37 in cream (O/W 
emulsion) could be achieved through this HPLC method. Our 
findings indicate that LL-37 cream (O/W emulsion) establishes good 
physical characteristics and stabilizes the active ingredient, 
especially at 4 °C and 28 °C storage. Therefore, the emulsion delivery 
system is harmless and stable.  
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